Heidelberg Pharma AG (XTER:HPHA) Total Liabilities: €61.12 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:HPHA Heidelberg Pharma AG XTER:HPHA
32 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Total Liabilities?

Heidelberg Pharma AG XTER:HPHA -1.92% 32 Total Liabilities is €61.12 Mil as of May. 2026. GuruFocus rates XTER:HPHA with a GF Score™ of 32/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Heidelberg Pharma AG's Total Liabilities for the quarter that ended in May. 2026 was €61.12 Mil.

Heidelberg Pharma AG's quarterly Total Liabilities declined from Nov. 2025 (€49.05 Mil) to Feb. 2026 (€45.93 Mil) but then increased from Feb. 2026 (€45.93 Mil) to May. 2026 (€61.12 Mil).

Heidelberg Pharma AG's annual Total Liabilities increased from Nov. 2023 (€21.01 Mil) to Nov. 2024 (€29.86 Mil) and increased from Nov. 2024 (€29.86 Mil) to Nov. 2025 (€49.05 Mil).

Heidelberg Pharma AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Total Liabilities Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 33.94 21.01 29.86 49.05

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.94 43.52 49.05 45.93 61.12
XTER:HPHA
32GF Score
Heidelberg Pharma AG XTER:HPHA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Heidelberg Pharma AG's Total Liabilities for the fiscal year that ended in Nov. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.21+(0.013+37.831
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=49.05

Total Liabilities=Total Assets (A: Nov. 2025 )-Total Equity (A: Nov. 2025 )
=38.136--10.918
=49.05

Heidelberg Pharma AG's Total Liabilities for the quarter that ended in May. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.158+(0.046+53.911
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=61.12

Total Liabilities=Total Assets (Q: May. 2026 )-Total Equity (Q: May. 2026 )
=46.895--14.219
=61.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €61.12 Mil mean?
Heidelberg Pharma AG (XTER:HPHA) has a Total Liabilities of €61.12 Mil as of May. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Total Liabilities too high?
Heidelberg Pharma AG's current Total Liabilities is €61.12 Mil. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Total Liabilities compare to VRTX and REGN?
Heidelberg Pharma AG's Total Liabilities of €61.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Total Liabilities is €61.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Total Liabilities is €61.12 Mil. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Total Liabilities is €61.12 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for XTER:HPHA:

  • Total Liabilities: €61.12 Mil
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score

Get the complete analysis for XTER:HPHA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value